Clinical Trials Logo
  1. Home
  2. Carcinoma, Non-Small-Cell Lung
  3. NCT00548093

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Carcinoma, Non Small Cell Lung Clinical Trial

Official title:
A PHASE 2, OPEN-LABEL, TWO ARM TRIAL TO EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS WITH ADVANCED NSCLC AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN AND FAILURE OF PRIOR TREATMENT WITH ERLOTINIB

Clinical Trial Summary

To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00548093
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date April 29, 2008
Completion date June 11, 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT02135211 - Healthy Directions After Lung Surgery Pilot N/A
Completed NCT00191230 - Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer Phase 2
Withdrawn NCT01004419 - Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer Phase 1
Completed NCT01671332 - Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer Phase 2
Terminated NCT00905801 - Computed Tomography (CT) Perfusion Imaging of Lung Cancer N/A
Recruiting NCT00184964 - Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis N/A
Completed NCT00191256 - Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer Phase 2
Completed NCT00954278 - Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer Phase 1
Terminated NCT01282151 - TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Phase 3
Terminated NCT01088906 - Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC Phase 2
Completed NCT00553254 - Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer Phase 2
Completed NCT01469000 - A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Phase 2
Withdrawn NCT00934076 - Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00798720 - Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT01891669 - A Study Of PF-06263507 In Patients With Advanced Solid Tumors Phase 1
Completed NCT00160069 - Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer Phase 2